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The animals used in liver fibrosis studies must usually be sacrificed. Ultrasound has been demonstrated to have the ability to
diagnose hepatic fibrosis and cirrhosis in experimental small-animal models. However, few studies have used high-frequency
ultrasound (HFU, 40MHz) to monitor changes in the rat liver and other hollow organs longitudinally. In this study, liver fibrosis
was induced by administering dimethylnitrosamine (DMN) in SD rats, aged 8 weeks, for three consecutive days per week for up to
4 weeks. A Chinese herbal medicine Yi Guan Jian (YGJ) was orally administered (1.8 g/kg daily) to DMN-induced liver fibrosis rats
for 2 weeks. Compared with the normal control rats, rats treated with DMN for either 2 weeks or 4 weeks had significantly lower
body weights, liver indexes and elevation of hydroxyproline, GOT, and GPT contents. YGJ herbal treatment remarkably prevented
rats from DMN-induced liver fibrosis. The HFU scoring results among the normal controls, 2-week DMN-treated rats, 4-week
DMN-treated rats, and combined 2-week YGJ therapy with 4-week DMN-treated rats also reached statistical significance. Thus,
HFU is an accurate tool for the longitudinal analysis of liver fibrosis progression in small-animal models, and the YGJmay be useful
in reversing the development of hepatic fibrosis.
1. Introduction
Hepatic fibrosis has been reported to be a response to necrosis
and inflammation caused by various factors such as infection,
intoxication, and detrimental factors. Hepatic fibrosis leads to
the activation of Kupffer cells, mononuclear cells, and hepatic
stellate cells, resulting in the degeneration of the hepatic
cords. The persistence of the insult disrupts the normal
hepatic architecture, leading to the development of regen-
erative nodules and vascular dysfunction, which are used
to determine the cirrhosis stage [1, 2]. Liver biopsy is the
major tool for diagnosing hepatic fibrosis or cirrhosis and
assessing the severity of an injured liver. However, this pro-
cedure has several drawbacks, including its invasiveness, the
likelihood of sampling errors, and the potential for medical
complications.
Ultrasound has been demonstrated to have the ability to
diagnose hepatic fibrosis and cirrhosis in experimental small-
animalmodels [3–6]. However, the ultrasonic frequency used
in these studies was always below 15MHz, and the quality
of the images was limited by the spatial resolution. High-
frequency ultrasound (HFU) imaging, a recent developed
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technology, allows the imaging of small laboratory animals
at a very high resolution [7, 8]. The frequency of such
systems is above 20MHz, and the spatial resolution is less
than 100 𝜇m [8–10]. One of the most important advantages
of this technology is the ability to image organs and tissue
noninvasively in living animals. This ability allows disease
progression in animalmodels to bemonitored in longitudinal
studies, which can shorten the observation time and reduce
the number of sacrificed animals [11]. In our previous study,
we identified the surgical anatomy of the rodent abdomen
using high-frequency ultrasound (40MHz) [12].
Traditional Chinese medicines (TCMs) are multi-
ingredient extracts with low side effects in the treatment of
chronic liver diseases [13, 14]. Yi Guan Jian (YGJ) decoction is
a complex prescription of TCM consisting of 9 medical herbs
[15, 16]. Although there is still no evidence-based clinical
study, YGJ has been used to treat human liver fibrosis
induced by hepatitis and has shown apparent efficacy in the
reversal of liver fibrosis. The major active components of
YGJ extract, ferulic acid, and catalpol, significantly inhibit
the progression of hepatic fibrosis in carbon tetrachloride-
(CCL4-) induced animal model study [17]. In addition, a
more clinical representation of liver fibrosis model showed
that the livers in dimethylnitrosamine- (DMN-) treated
animals were shrunken with dark discoloration because
of congestion [18]. However, the therapeutic effects of YGJ
extract in the DMN-induced liver fibrogenesis have not been
fully clarified.
In the present study, we used a commercially available
high-frequency (40MHz) ultrasound imaging system to
detect and monitor the progression of hepatic fibrosis in
vivo in the normal controls, 2-week DMN-treated rats, 4-
week DMN-treated rats, and combined 2-week YGJ therapy
with 4-week DMN-treated rats. The therapeutic effects of
YGJ extract for liver fibrosis were extensively evaluated on
histological examination, biochemical values, and hepatic
fibrosis-related gene regulations.
2. Methods
2.1. Animal Model. Twenty male Sprague-Dawley (SD) rats
(aged 8 weeks and weighing 250–300 g) were used. The
animals were housed in an air-conditioned room at 23 ± 3∘C
with 55–60% relative humidity and a 12 h light/dark cycle.
This study conformed to “The Guide for the Care and Use
of Laboratory Animals” and was approved by the Ethics
Committee of National Chung Hsing University (Approval
no. 102-10). Two distinct models of experimental hepatic
fibrosis were established in rats, one using DMN and one
using normal saline (control group). In the DMN-induced
fibrosis group, the rats were injected intraperitoneally with 1%
DMN (10mg/kg body weight) for three consecutive days per
week for 2 weeks or 4 weeks as described previously [15, 19].
After treatment with DMN for 2 weeks, rats were orally
administered 1.8 g/kg YGJ herbal extract (Koda Pharmaceu-
tics Ltd., Taoyuan, Taiwan). The mock control group was
given the same volume of phosphate-buffered saline (PBS)
intraperitoneally for 4 weeks. The rats were sacrificed after
2 or 4 weeks of treatment with DMN or normal phosphate-
buffered saline (PBS) or combined with YGJ herbal therapy.
2.2. High-Frequency Ultrasound (HFU) Examination. Ani-
mals were lightly anesthetizedwith 2.0–2.5% isoflurane vapor
and placed in the supine position while breathing sponta-
neously. After the rats were anesthetized, the abdomen was
shaved and further cleaned with a chemical hair remover to
minimize ultrasound attenuation [19]. A commercially avail-
able HFU system (Visual Sonics Vevo 770, Toronto, Ontario,
Canada) was used in this experiment. A transducer with a
central frequency of 40MHz, providing an axial resolution
of 40𝜇m with a 14.6mm field of view, was used to image the
rat’s abdominal organs.When beginning to perform theHFU
analysis, ultrasound gel was put on the skin as a coupling
fluid.
2.3. Longitudinal Evaluation of the Abdominal Organs by
HFU. HFU was used to assess each rat on the first day of the
10th and 12th weeks of age. Each rat’s abdomen was scanned
carefully by three experienced researchers. The liver was
examined to assess echogenicity, homogeneity, the surface
of the margin, and intrahepatic vascular abnormalities. In
addition, the size of the spleen and the presence or absence
of ascites were also examined and recorded.
2.4. Ultrasound Scoring System. To evaluate the validity of
HFU for the diagnosis of cirrhosis, we scored the ultrasono-
graphic findings for the rats using a modified scoring system
[20]. Items including the liver parenchyma echotexture,
spleen size, ascites, vasculature, and the surface of the margin
were used to score the severity of cirrhosis. The detailed
scoring method is presented in Table 1.
2.5. Histological Examinations. To validate the in vivo imag-
ing findings, rats were sacrificed, and their livers were excised
immediately. To correlate the size and location of the previ-
ously observed lesions, visual inspection and ex vivoUSof the
liver were performed. The liver index (liver wet weight/body
weight) and spleen index (spleen wet weight/body weight)
were calculated. Liver tissue slices were fixed for 5 hours
in Bouin’s solution, followed by overnight exposure to 10%
buffered formalin solution, pH 7.2, and then embedded in
paraffin. Liver samples were sectioned (5 𝜇m) and stained
with hematoxylin and eosin (H&E) and picrosirius according
to standard protocols [21–23]. Masson’s trichrome and Sirius
Red staining were used to assess collagen deposition [15].
2.6. Tissue Hydroxyproline and Blood Biochemical Assays.
Serum glutamate oxaloacetate transaminase (GOT) and
glutamic pyruvic transaminase (GPT) concentrations were
determined using a JSCC kit (Roche, Indianapolis, IN,
USA). The hepatic hydroxyproline content was measured as
described previously [15].
2.7. Detection of Fibrogenesis-Related mRNA by Quantitative
RT-PCR. The mRNA expression of the fibrogenesis genes,
alpha-smooth muscle actin (𝛼-SMA) and collagen alpha-1(1)
(collagen 𝛼1-I) was determined by semiquantitative RT-PCR.
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Table 1: Scoring system for high-frequency ultrasound (HFU) signs
for the assessment of liver fibrosis.
Characteristic US sign Score
Parenchymal
echotexturea
Homogeneous echotexture 0
Heterogeneous echotexture 1
Coarse echotexture 2
Spleen sizeb
Normal 0
Enlarged 1
Ascitesc Absence 0
Presence 1
Vasculatured
Normal 0
Obscure with normal diameter 1
Stretched or broad vessels 2
Surface or
margine
Smooth 0
Irregular 1
The cirrhosis score was determined as follows.
aLiver parenchyma (hepatic parenchyma away from major vessel or bile
duct were used in evaluation): 0 score for homogenous appearance of the
parenchyma; 1 score for heterogenous with finely scattered hypoechoic and
hyperechoic areas; 2 score for coarse liver with irregular or patchy pattern.
bSpleen size index (calculated as product of oblique and diagonal diameter):
0 score for spleen size index <1.7 cm2; 1 score for larger spleen.
cAscites: 0 score for absence of ascites; 1 score for presence of ascites.
dVasculature: 0 score for smooth vessel wall; 1 score for obscured or blurred
vessel with normal diameter; 2 score for irregular and narrowed vessel.
eSurface of margin: 0 score for smooth surface; 1 score for uneven surface or
shallow, irregular nodular surface.
The housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control. Approx-
imately 900 ng of total RNA extracted from liver tissue
was reverse transcribed with MuLV Reverse Transcriptase
using the GeneAmp RNA PCR Kit (Applied Biosystems,
Foster, CA, USA) and oligo d(T)16 primers. Aliquots of the
reverse transcriptase mix were used for PCR amplification
of 𝛼-SMA (5󸀠-TGGCTATTCCTTCGTGACTACTG-3󸀠 and
5󸀠-AAAGATGGCTGGAAGAGAGTCAC-3󸀠), collagen 𝛼1-I
(5
󸀠
-GTTCGTGACCGTGACCTTGA-3󸀠 and 5󸀠-TTGGGG-
TTCGGGCTGATGTA-3󸀠), and GAPDH (5󸀠-ATCCCC-
AGAGCGTCATTCG-3󸀠 and 5󸀠-GAGAGAGCCCTGCCT-
GCC-3󸀠). The transcription levels of each gene were normal-
ized against those of GAPDH mRNA using a semiquantita-
tive method as described previously [15, 24].
2.8. Statistical Analysis. The results were expressed as the
mean ± standard deviation (SD).The differences between the
DMN-treated group and the control group were evaluated
using Student’s 𝑡-test. Statistical significance was set at 𝑃 <
0.05 (∗ or #).
3. Results
3.1. Correlation of Gross Liver Characteristics and HFU Image
Findings In Vivo in Control and DMN-Treated Rats. In
Figure 1, panel (A) presents the gross appearance of a normal
liver, panel (B) presents the gross appearance of the 2-
week DMN-treated rat liver, and panel C presents the gross
(A)
(a)
(B)
(b)
(C)
(c)
Figure 1:The gross appearance of a normal liver (A), 2-week DMN-
treated liver (B), and 4-week DMN-treated liver (C). Panels (a), (b),
and (c) are the ultrasonographic images (40MHz) corresponding to
panels (A), (B), and (C), respectively.The echogenicity of the DMN-
treated rat livers wasmore hyperechoic than that of normal rat livers.
appearance of 4-week DMN-treated rat liver. Panels (a), (b),
and (c) show the ultrasonographic images corresponding to
the photographs in panels (A), (B), and (C), respectively. In
the normal rats (Figure 1(A)), the liver was a soft, pinkish-
brown organ consisting of major four lobes (the median lobe,
right lobe, left lobe, and caudate lobe). In the 2-week DMN-
treated rats, the liver’s surface was relatively darker than that
in the normal rats, and the margin of the liver was coated
with a yellowish material (Figure 1(B)). In the 4-week DMN-
treated rats, the liver was smaller and relatively dark brown
and was coated with yellowish material along the fissures
and margins (Figure 1(C)). In the ultrasonographic images,
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Figure 2: The normal lobular architecture with central veins and radiating hepatic cords was observed in normal control rats ((A), (a), (D),
and (d)). Fatty degeneration, necrosis, the infiltration of inflammatory cells, and the apparent formation of fibrotic septa were present in the
2-week DMN-treated group ((B), (b), (E), and (e)) and 4-week DMN-treated group ((C), (c), (F), and (f)). Tissue stained with H&E and
imaged at 100x ((A), (B), and (C)) or 400x ((a), (b), and (c)) magnifications. Tissue stained with Masson’s trichrome and imaged at 100x ((D),
(E), and (F)) or 400x ((d), (e), and (f)) magnifications.
the normal liver parenchyma had a uniform, sponge-like
texture with low echogenicity (Figure 1(a)). Passing through
the parenchyma were blood vessels, which were observed as
branching tubular structures that could be traced toward the
portal or hepatic vein. In the 2-week DMN-treated fibrotic
rats, the ultrasonographic images of the liver were relatively
hyperechoic (Figure 1(b)). The most hyperechoic pattern was
observed for the 4-week DMN-treated rat livers (Figure 1(c)).
In addition, ascites was also detected by ultrasound in the 4-
week DMN-treated rat livers (Figure 1(c)).
3.2. Pathological Features in Normal Control and DMN-
Treated Rats. To assess the reliability of HFU imaging,
we performed hematoxylin and eosin (H&E) staining and
Masson’s trichrome staining to examine pathological alter-
ations and collagen deposition (Figure 2).The normal lobular
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architecture with central veins and radiating hepatic cords
was observed in the livers of normal control rats (Figures
2(A), 2(a), 2(D), and 2(d)). Fatty degeneration, necrosis, the
infiltration of inflammatory cells, and the apparent formation
of fibrotic septa were present in the 2-week DMN-treated
group (Figures 2(B), 2(b), 2(E), and 2(e)) and became more
severer in the 4-weekDMN-treated group (Figures 2(C), 2(c),
2(F), and 2(f)).
3.3. HFU Analysis of Associated Organs. The livers of either
2-week (Figures 3(E), 3(e), 3(F), and 3(f)) or 4-week (Figures
3(I), 3(i), 3(J), and 3(j)) DMN-treated rats were relatively
smaller than those of the normal rats (Figures 3(A), 3(a),
3(B), and 3(b)). The ultrasonographic images of the spleens
of DMN-treated rats showed increased echogenicity (Figures
3(G), 3(g), 3(K), and 3(k)). The kidneys were also hypere-
chogenic in DMN-treated rats (Figures 3(H), 3(h), 3(L), and
3(l)). Ascites was frequently detected in the DMN-treated
rats.
3.4. Ultrasound Scoring to Evaluate YGJTherapeutic Effect. In
the modified scoring system, the normal control rats were
scored as 0. After 2weeks of treatmentwithDMN, the average
score was 1.6 ± 0.9, and after 4 weeks of DMN treatment,
it was increased to 6.2 ± 0.8. As shown in Table 2, we can
see that the ultrasound score was significantly different in
the 2-week DMN-treated rats (𝑃 < 0.05) and the 4-week
DMN-treated rats (𝑃 < 0.01) compared to normal control
rats. The average score of the 4-week DMN-treated and 2-
week YGJ therapy group was significantly decreased (2.8 ±
0.8, 𝑃 < 0.05) compared to the 4-week DMN-treated rats
without YGJ therapy. To evaluate interobserver and intraob-
server variability in the HFU imaging assessment of the
severity of fibrotic liver, three experienced operators inde-
pendently graded the hepatic images as normal, fibrosis, or
cirrhosis. Weighted kappa statistics were used to analyze
interobserver and intraobserver agreement as shown in
Tables S1 and S2 in Supplementary Material available online
at http://dx.doi.org/10.1155/2013/302325. Results showed that
the intraobserver agreement was 70–100% (𝜅 = 0.53–1.0)
and interobserver agreement was even higher from 93% to
100% (𝜅 = 0.85–1.0). Therefore, this is a reliable sonographic
assessment method for rat liver fibrosis and cirrhosis.
3.5. Physical and Biochemical Characteristics of the Normal,
DMN-Treated, and DMN-Treated Combined YGJ Therapy
Rats. As shown in Table 3, rats treated with DMN for either 2
weeks or 4 weeks were significantly different from the control
rats in the terms of bodyweight, spleen index, hydroxyproline
level, GOT level, and GPT level. However, rats treated with
DMN and combined with 2 weeks YGJ therapy significantly
decreased serum GOT and GPT levels and restored body
weight compared to the DMN-treated without YGJ therapy
group (𝑃 < 0.05). Moreover, the hepatic hydroxyproline
concentration in the 4-week DMN-treated group increased
5.6-fold over the normal control group (𝑃 < 0.001) but
significantly decreased in the YGJ therapeutic group (𝑃 <
0.01) compared to the DMN-treated alone group.
3.6. Effects of YGJ Herbal Therapy on Liver Histological
Changes. Liver histopathological analyses consisted of tissue
section staining with H&E and Masson’s trichrome dye and
combined with HFU imaging analysis as shown in Figure 4.
Liver tissue from 4-week DMN-treated rats had more steato-
sis, fibrotic septa, necrotic hepatocytes, and incorporation
of degenerated hepatocytes into pseudolobules as well as
associated higher collagen content (Figures 4(g), 4(h), and
4(i)) than that of normal control rats (Figures 4(a), 4(b), and
4(c)) and 2-week DMN-treated rats (Figures 4(d), 4(e), and
4(f)). However, 4-week DMN-treated rats combined with
YGJ herbal therapy for 2 weeks markedly alleviated the
degree of liver fibrosis and significantly reduced the collagen
deposition (Figures 4(j), 4(k), and 4(l)).
3.7. Effects of YGJ on Gene Expression of 𝛼-SMA and Collagen
𝛼1-I. Gene expression for 𝛼-SMA and collagen 𝛼1-I, which
represent hepatic fibrosis factors, was analyzed using RT-PCR
(Figure 5(a)). The mRNA levels of 𝛼-SMA and collagen 𝛼1-
I were increased in either 2-week DMN-treated rats (1.5-
and 1.7-fold) or 4-week (3.6- and 1.9-fold) DMN-treated rats,
respectively, compared with the normal control group (𝑃 <
0.05). The YGJ herbal treatment significantly reduced the
mRNA levels of 𝛼-SMA and collagen 𝛼1-I by 67% (𝑃 < 0.01)
and 45% (𝑃 < 0.05), respectively compared with the 4-week
DMN-treated alone group (Figure 5(b)).
4. Discussion
In the current study, we demonstrated that high-frequency
ultrasound (HFU, 40MHz) imaging is a useful tool for the
in vivo analysis of liver tissue during chronic toxin exposure
and the induction of liver fibrosis in rats. In addition, we
developed an ultrasound scoring system to help assess the
severity of liver fibrosis in rats.Themean HFU imaging score
increased with increasing fibrosis stage. It is a useful tool to
evaluate the therapeutic efficacy of the YGJ herbal medicine
treatment.
Small animals have been used as models for the inves-
tigation of toxin- or virus-induced liver injury for decades
[25–28]. To confirm the pathological findings of liver damage,
the majority of studies have sacrificed animals in the exper-
imental and control groups at different time points during
the study. This type of study design has two drawbacks.
First, it lacks continuity. For example, mouse A is sacrificed
after 2 weeks of toxin exposure, and mouse B is sacrificed
after four weeks of toxin exposure. In this situation, we
usually regard the pathological changes exhibited by mouse
B as the continuation of the changes observed in mouse
A. However, even if the animals belong to the same strain,
there may be some bias. Second, this type of study design
requires many more animal sacrifices. If a study does not use
imaging to assess animals, animalsmust be sacrificed at every
observational and interventional time point.
Ultrasound has been used to analyze the livers of small
animals for a long history [29, 30]. Initially, researchers
found that diffuse liver disease appears ultrasonographically
as a change in the liver’s echogenicity relative to that of the
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Figure 3: Ultrasonographic images (40MHz) of normal control rats, 2-week DMN-treated rats, and 4-week DMN-treated rats. ((A), (B), (C),
and (D)) The HFU images of the normal rat inferior right liver (IRL), lateral left liver (LLL), spleen (Sp), and left kidney (Ki), respectively.
Panels (a), (b), (c), and (d) are the schematic diagrams of panels (A), (B), (C), and (D), respectively. ((E), (F), (G), and (H))The 2-week DMN-
treated rat inferior right liver, lateral left liver, spleen, and left kidney, respectively. Panels (e), (f), (g), and (h) are the schematic diagrams of
panels (E), (F), (G), and (H), respectively. ((I), (J), (K), and (L)) The 4-week DMN-treated rat inferior right liver, lateral left liver, spleen, and
left kidney, respectively. Panels (i), (j), (k), and (l) are the schematic diagrams of panels (I), (J), (K), and (L), respectively.
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Table 2: Ultrasound characteristics (40MHz) of fibrosis in normal liver, 2-weekDMN-treated fibrotic liver, and 4-weekDMN-treated fibrotic
liver.
Treatment Parenchymal echotexture Spleen size Ascites Surface or margin Vasculature Sum Average†
Normal control
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
DMN-induced
fibrosis (2 wk)
1 0 0 0 0 1
0 0 0 0 1 1
1 0 0 0 0 1 1.6 ± 0.9∗
1 0 1 0 0 2
1 1 0 0 1 3
DMN-induced
fibrosis (4 wk)/PBS
(2wk)
2 1 1 1 2 7
2 1 1 0 2 6
2 1 0 1 2 6 6.2 ± 0.8∗∗
2 1 1 1 2 7
1 1 0 1 2 5
DMN-induced
fibrosis (4 wk)/YGJ
(2wk)
0 0 1 1 1 3
0 0 1 0 1 2
1 1 0 1 1 4 2.8 ± 0.8∗,#
0 1 1 0 0 2
1 1 0 0 1 3
†Each value represents the mean ± SEM of five rats.
∗P < 0.05, ∗∗P < 0.01 versus normal control.
#P < 0.05 versus DMN-induced fibrosis/PBS group.
Table 3: Body weight, liver index, spleen index, hydroxyproline level, GOT level and GTP level in the normal control group, 2-week DMN-
treated group, and 4-week DMN-treated group.
Treatment† Normalcontrol
DMN-induced
fibrosis (2 wk)
DMN-induced fibrosis
(4 wk)/PBS (2wk)
DMN-induced
fibrosis (4 wk)/YGJ (2wk)
Body weight (g) 471.3 ± 42.9 411.3 ± 34.7∗ 341.7 ± 40.4∗∗ 418.7 ± 36.9∗,#
Liver index (%) 4.2 ± 0.3 4.1 ± 0.4 3.5 ± 0.7∗∗ 4.3 ± 0.8##
Spleen index (%) 0.2 ± 0.0 0.5 ± 0.1∗∗ 0.4 ± 0.1∗ 0.4 ± 0.1∗
Hydroxyproline (𝜇g/g liver) 208.7 ± 19.5 452.2 ± 67.8∗∗ 1187.1 ± 220.1∗∗∗ 403.5 ± 61.3∗,##
GOT (U/L) 57.2 ± 1.7 175 ± 22.4∗∗∗ 136.8 ± 6.4∗∗ 71.9 ± 8.3∗,#
GPT (U/L) 39.0 ± 7.1 83.4 ± 11.0∗∗ 97.8 ± 10.5∗∗ 52.0 ± 7.7∗,#
†Each value represents the mean ± SEM of five rats.
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus normal control.
#P < 0.05, ##P < 0.01 versus DMN-induced fibrosis/PBS group.
renal cortex or spleen. To precisely assess the severity of
liver disease, some quantitative methods and tools have been
developed. Matsuhashi and colleagues found that the speed
of the sound is useful for diagnosing fatty liver and cirrhosis
[6]. Guimond et al. confirmed that quantitative ultrasonic
tissue characterization can be used as a tool to continuously
monitor chronic liver remodeling in mice [3]. Wang et
al. suggested that stiffness measurements using acoustic
radiation force can provide a quantitative assessment of the
extent of fibrosis in the liver and can potentially be used for
the diagnosis, management, and study of liver fibrosis [31].
Ho et al. suggested that ultrasound Nakagami imaging is a
functional imaging tool to complement the use of conven-
tional B-scanning in animal studies of liver fibrosis [32].
However, all studies mentioned above require the use of
complicated or specific techniques or instruments. Due to
technical advances, HFU, which refers to frequencies
above 20MHz, has become more readily available [7–10].
Ferna´ndez-Domı´nguez et al. reported that diagnostic HFU
is an effective method for monitoring the progression of liver
disease from steatosis to hepatocellular carcinoma in mice
[33]. Similar to the results of their study, we found that HFU
can be used as a noninvasive tool to monitor liver disease
progression in rats.
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Figure 4: Pathological features for effects of the YGJ herbal therapy on DMN-induced liver fibrosis. ((a), (b), and (c)) The normal lateral left
liver architecture with central veins and radiating hepatic cords was observed in normal control rats. ((d), (e), and (f)) Fatty degeneration,
necrosis, infiltration of inflammatory cells, and apparent formation of fibrotic septa were present in the 2-week DMN-treated group. ((g), (h),
and (i)) The more severer fibrotic liver architecture images were present in the 4-week DMN-treated group. ((j), (k), and (l)) The degree of
liver fibrosis was significantly reduced in the YGJ-treated group. ((a), (d), (g), and (j)) Lateral left liver architectures of HFU (40MHz) images.
((b), (e), (h), and (k)) Tissues stained with H&E, bar = 2.0mm. ((c), (f), (i), and (l)) Tissues stained with Masson’s trichrome, bar = 2.0mm.
One study showed that both low-frequency (2–5MHz)
and high-frequency probes (5–12MHz) were reliable and
effective alternatives to the histological staging of chronic
liver diseases [34]. However, our study using a 40MHz
probe showed that the images had a higher resolution than
those obtained with 20MHz probes and that it was easier
to monitor the detailed changes in disease progression using
the 40MHz probe. Another advantage of the 40MHz probe
is that the rat’s spleen can be easily detected. When using a
20MHz probe, the acoustic waves are hampered by the rat’s
ribs.
The use of an ultrasound scoring system is a reliable
method for evaluating the severity of diffuse liver disease in
humans and small animals [5, 35, 36]. Yan et al. reported
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Figure 5: Fibrotic gene expression levels of𝛼-SMA andCol𝛼-1.I in normal control rats, DMN-induced fibrosis rats, andYGJ herb-treated rats.
(a) Gene expression patterns were amplified by semiquantitative RT-PCR in four different groups including the normal control rats, 2-week
DMN-treated rats, 4-week DMN-treated with 2-week PBS rats, and 4-week DMN-treated with 2-week YGJ rats (𝑛 = 5). (b) The expression
levels of 𝛼-SMA and Col 𝛼-1.I were quantified using densitometry. Values were normalized against those forGAPDHmRNA expression as an
internal calculation control. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 compared with the normal control group. #𝑃 < 0.05; ##𝑃 < 0.01 compared with 4-week
DMN-treated group.
that an ultrasound scoring system, especially when com-
bined with computed tomography (CT) and serum fibrosis
markers, had a higher value in the noninvasive quantitative
diagnosis of hepatic fibrosis in longitudinal studies [5]. In
our study, the scores were significantly different between the
normal control, 2-week DMN-treated, and 4-week DMN-
treated rats. To reduce the bias of the interpretation of the
ultrasound images, operators have to practice using the HFU
system for at least 3 weeks before initiating a study. In
addition, ultrasound images were recorded and analyzed by
two operators working based on consensus.
According to Chinese medicinal theory, liver disease is
caused by an epidemic pathogen and dampness heat and
would result in stasis of the blood [37]. When liver disease
progresses to liver cirrhosis, the result is a blood deficiency.
Serum activity ofGOT andGPT are themost commonly used
biochemical markers of liver injuries [38].The present exam-
ination of the progress of liver injury induced by a repeated
administration of DMN found that both serum GOT
and GPT activities markedly increased. The YGJ herbal ther-
apy clearly repressedDMN-inducedGOT andGPT activities,
indicating that the YGJ extract has potent hepatoprotec-
tive effects. Hepatic hydroxyproline content, 𝛼-SMA, and
collagen 𝛼-1.I gene expression measurements also demon-
strated that YGJ extract treatment significantly decreased the
accumulation of collagen compared with the DMN-treated
and PBS-administrated groups. The pathological changes of
liver tissue obviously improved with YGJ extract treatment,
indicating the inhibitory effect of the YGJ extract on hepatic
fibrosis.
5. Conclusions
It is evident that HFU provides higher-resolution images
for monitoring the progression of liver disease in rats. The
use of HFU may reduce the number of invasive procedures
required and reduces the number of sacrificed animals. In
addition, the ultrasound scoring system based on HFU is
useful for detecting, grading, andmonitoring the progression
of liver disease in rats, and the results of this system correlate
well with pathological findings. We also demonstrated that
the primary mechanism of YGJ therapeutic effect could be
protection against hepatic injury via reduced serum levels of
GOT and GPT as well as reduction of the activated HSCs
via downregulation of 𝛼-SMA and collagen 𝛼-1.I mRNA
expressions. It provides scientific evidence for the clinical use
of YGJ extract in treating liver fibrosis and cirrhosis.
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